Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory 

We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical Industries Limited’s share was trading at $20.21 as of October 8th. TEVA’s trailing and forward P/E were 872.00 and 7.06 respectively according to Yahoo Finance.

Eli Lilly and Company (LLY) Diabetes Medication Successful in Children and Adolescents

Teva Pharmaceutical Industries (TEVA) is emerging as a compelling turnaround story, transitioning from a debt-laden generics player to a focused branded and specialty company with momentum in neuroscience. Market activity underscores this shift, with institutional investors showing significant bullish positioning in October 2025 call options. Technically, the stock has recovered past $20, holding above key moving averages, signaling a constructive setup.

Central to Teva’s transformation is Ajovy, its anti-CGRP therapy for migraine prevention, which continues to deliver steady growth with expected quarterly sales around $70 million. Ajovy is establishing a durable presence in a large and expanding migraine market, benefiting from improved access dynamics and flexible dosing options, giving it a long runway despite competition from Lilly and Amgen.

Even more promising is Teva’s long-acting injectable (LAI) olanzapine program, TEV-749. Phase 3 SOLARIS trial data demonstrated robust efficacy across schizophrenia endpoints and, importantly, no instances of the historical post-injection delirium/sedation syndrome due to Teva’s SteadyTeq® technology. With LAIs currently underpenetrated, TEV-749 alongside UZEDY could capture significant market share, potentially generating $1.5–2.0 billion in peak sales and reshaping Teva’s branded psychiatry franchise.

Financially, Teva is strengthening, with 2025 revenues projected near $17 billion, EPS around $2.60, EBIT margins approaching 27%, and free cash flow growth. Net debt has declined from over $18 billion to approximately $11 billion, with further deleveraging expected, bringing leverage close to 1x Net Debt/EBITDA. Trading at roughly 7x 2025 earnings, Teva offers a rare combination of value and growth.

With steady performance from Ajovy and Austedo and a potential blockbuster in TEV-749, Teva is moving beyond its generics legacy. The convergence of pipeline progress, technical strength, and improving fundamentals positions the stock for a potential re-rating, making the current price an attractive entry point for investors seeking both growth and value.

Previously we covered a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) by Kontra in May 2025, which highlighted the company’s shift from generics toward branded and specialty medicines, strong revenue growth, and operational improvements. The company’s stock price has appreciated approximately by 20% since our coverage. The thesis still stands as momentum in neuroscience continues. Kontra emphasizes TEV-749 and technical strength as new catalysts.

Teva Pharmaceutical Industries Limited is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 57 hedge fund portfolios held TEVA at the end of the second quarter which was 64 in the previous quarter. While we acknowledge the risk and potential of TEVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TEVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW

Disclosure: None.